SEHK:6826

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Shanghai Haohai Biological Technology

Executive Summary

Shanghai Haohai Biological Technology Co., Ltd. More Details

Rewards

PE ratio (30x) is below the Biotechs industry average (61x)

Earnings are forecast to grow 12.9% per year

Risk Analysis

No risks detected for 6826 from our risk checks.


Snowflake Analysis

Excellent balance sheet and slightly overvalued.

Share Price & News

How has Shanghai Haohai Biological Technology's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: 6826 is not significantly more volatile than the rest of Hong Kong stocks over the past 3 months, typically moving +/- 6% a week.

Volatility Over Time: 6826's weekly volatility (6%) has been stable over the past year.


Market Performance


7 Day Return

-3.8%

6826

2.4%

HK Biotechs

1.1%

HK Market


1 Year Return

3.6%

6826

21.7%

HK Biotechs

8.3%

HK Market

Return vs Industry: 6826 underperformed the Hong Kong Biotechs industry which returned 21.7% over the past year.

Return vs Market: 6826 underperformed the Hong Kong Market which returned 8.3% over the past year.


Shareholder returns

6826IndustryMarket
7 Day-3.8%2.4%1.1%
30 Day3.0%-7.2%5.6%
90 Day-20.5%-11.0%3.7%
1 Year5.8%3.6%22.0%21.7%12.8%8.3%
3 Year31.1%25.4%38.9%37.1%-2.8%-12.9%
5 Year9.5%2.0%47.6%44.2%30.6%8.5%

Long-Term Price Volatility Vs. Market

How volatile is Shanghai Haohai Biological Technology's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Shanghai Haohai Biological Technology undervalued compared to its fair value and its price relative to the market?

29.96x

Price to Earnings (PE) ratio


Share Price vs. Fair Value

Below Fair Value: 6826 (HK$46.4) is trading above our estimate of fair value (HK$11.66)

Significantly Below Fair Value: 6826 is trading above our estimate of fair value.


Price To Earnings Ratio

PE vs Industry: 6826 is good value based on its PE Ratio (30x) compared to the XA Biotechs industry average (61x).

PE vs Market: 6826 is poor value based on its PE Ratio (30x) compared to the Hong Kong market (11.1x).


Price to Earnings Growth Ratio

PEG Ratio: 6826 is poor value based on its PEG Ratio (2.3x)


Price to Book Ratio

PB vs Industry: 6826 is good value based on its PB Ratio (1.3x) compared to the HK Biotechs industry average (4.3x).


Next Steps

Future Growth

How is Shanghai Haohai Biological Technology forecast to perform in the next 1 to 3 years based on estimates from 3 analysts?

12.9%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: 6826's forecast earnings growth (12.9% per year) is above the savings rate (1.6%).

Earnings vs Market: 6826's earnings (12.9% per year) are forecast to grow slower than the Hong Kong market (22.1% per year).

High Growth Earnings: 6826's earnings are forecast to grow, but not significantly.

Revenue vs Market: 6826's revenue (14.4% per year) is forecast to grow faster than the Hong Kong market (13.8% per year).

High Growth Revenue: 6826's revenue (14.4% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: 6826's Return on Equity is forecast to be low in 3 years time (8%).


Next Steps

Past Performance

How has Shanghai Haohai Biological Technology performed over the past 5 years?

-11.3%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: 6826 has high quality earnings.

Growing Profit Margin: 6826's current net profit margins (17.3%) are lower than last year (22.9%).


Past Earnings Growth Analysis

Earnings Trend: 6826's earnings have declined by 11.3% per year over the past 5 years.

Accelerating Growth: 6826's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Earnings vs Industry: 6826 had negative earnings growth (-34.1%) over the past year, making it difficult to compare to the Biotechs industry average (12.2%).


Return on Equity

High ROE: 6826's Return on Equity (3.7%) is considered low.


Next Steps

Financial Health

How is Shanghai Haohai Biological Technology's financial position?


Financial Position Analysis

Short Term Liabilities: 6826's short term assets (CN¥3.7B) exceed its short term liabilities (CN¥420.1M).

Long Term Liabilities: 6826's short term assets (CN¥3.7B) exceed its long term liabilities (CN¥138.7M).


Debt to Equity History and Analysis

Debt Level: 6826's debt to equity ratio (1.2%) is considered satisfactory.

Reducing Debt: Insufficient data to determine if 6826's debt to equity ratio has reduced over the past 5 years.

Debt Coverage: 6826's debt is well covered by operating cash flow (391.4%).

Interest Coverage: 6826 earns more interest than it pays, so coverage of interest payments is not a concern.


Balance Sheet


Next Steps

Dividend

What is Shanghai Haohai Biological Technology current dividend yield, its reliability and sustainability?

1.78%

Current Dividend Yield


Dividend Yield vs Market

Notable Dividend: 6826's dividend (1.78%) isn’t notable compared to the bottom 25% of dividend payers in the Hong Kong market (2.23%).

High Dividend: 6826's dividend (1.78%) is low compared to the top 25% of dividend payers in the Hong Kong market (6.66%).


Stability and Growth of Payments

Stable Dividend: Whilst dividend payments have been stable, 6826 has been paying a dividend for less than 10 years.

Growing Dividend: 6826's dividend payments have increased, but the company has only paid a dividend for 5 years.


Current Payout to Shareholders

Dividend Coverage: With its reasonable payout ratio (53.4%), 6826's dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: Insufficient data to determine if a dividend will be paid in 3 years and that it will be covered by earnings.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

6.0yrs

Average management tenure


CEO

Jianying Wu (56 yo)

10.33yrs

Tenure

CN¥1,519,000

Compensation

Dr. Jianying Wu has been General Manager and Executive Director of Shanghai Haohai Biological Technology Co., Ltd. since July 23, 2010. Mr. Wu worked as a surgeon at the General Surgery Department of the S...


CEO Compensation Analysis

Compensation vs Market: Jianying's total compensation ($USD231.42K) is below average for companies of similar size in the Hong Kong market ($USD660.36K).

Compensation vs Earnings: Jianying's compensation has been consistent with company performance over the past year.


Leadership Team

NamePositionTenureCompensationOwnership
Yongtai Hou
Executive Chairman10.33yrsCN¥1.39m3.4%
CN¥ 698.2m
Jianying Wu
GM & Executive Director10.33yrsCN¥1.52m3.4%
CN¥ 698.2m
Minjie Tang
CFO & Executive Director3.75yrsCN¥1.26m0.0040%
CN¥ 813.9k
Yiyi Chen
Executive Director10.33yrsCN¥1.01m0.23%
CN¥ 46.5m
Caixia Ren
Deputy General Manager10.33yrsno datano data
Wenbin Wang
Deputy General Manager1.67yrsno datano data
Jundong Zhang
Deputy General Manager1.67yrsno datano data
Ming King Chiu
Joint Company Secretary6yrsno datano data
Min Tian
Joint Company Secretary0.92yrno datano data

6.0yrs

Average Tenure

46yo

Average Age

Experienced Management: 6826's management team is seasoned and experienced (6 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Yongtai Hou
Executive Chairman10.33yrsCN¥1.39m3.4%
CN¥ 698.2m
Jianying Wu
GM & Executive Director10.33yrsCN¥1.52m3.4%
CN¥ 698.2m
Minjie Tang
CFO & Executive Director3.75yrsCN¥1.26m0.0040%
CN¥ 813.9k
Yiyi Chen
Executive Director10.33yrsCN¥1.01m0.23%
CN¥ 46.5m
Yingqi Li
Independent Non-Executive Director0.42yrno datano data
Jie You
Non Executive Director10.33yrsno data45.14%
CN¥ 9.3b
Ming Ping Huang
Non-Executive Director10.33yrsCN¥858.00k1.13%
CN¥ 232.7m
Yuanzhong Liu
Chairman of the Supervisory Committee10.33yrsno data1.13%
CN¥ 232.7m
Lei Zhao
Independent Non-Executive Director0.42yrno datano data
Zhi Su
Independent Non-Executive Director0.42yrno datano data
Zhihong Jiang
Independent Non-Executive Director0.42yrno datano data
Yushe Yang
Independent Non-Executive Director0.42yrno datano data

7.0yrs

Average Tenure

48.5yo

Average Age

Experienced Board: 6826's board of directors are considered experienced (7 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Shanghai Haohai Biological Technology Co., Ltd.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Shanghai Haohai Biological Technology Co., Ltd.
  • Ticker: 6826
  • Exchange: SEHK
  • Founded: 2007
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: HK$20.552b
  • Shares outstanding: 176.62m
  • Website: https://www.3healthcare.com

Number of Employees


Location

  • Shanghai Haohai Biological Technology Co., Ltd.
  • WenGuang Plaza
  • 23rd Floor
  • Shanghai
  • Shanghai Province
  • China

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
6826SEHK (The Stock Exchange of Hong Kong Ltd.)YesForeign Shares-Foreign ListedHKHKDApr 2015
5HBDB (Deutsche Boerse AG)YesForeign Shares-Foreign ListedDEEURApr 2015
688366SHSE (Shanghai Stock Exchange)Domestic SharesCNCNYOct 2019

Biography

Shanghai Haohai Biological Technology Co., Ltd. engages in the research and development, manufacture, and sale of biomedical materials in Mainland China, the United States, the United Kingdom, and internat...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/11/23 12:59
End of Day Share Price2020/11/23 00:00
Earnings2020/09/30
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.